

Contact: Hariharan Subramanian
AtheroSolve, Inc.
Phone: (617) 553-1015
701 Concord Avenue
Cambridge, MA 02138
info@atherosolve.com
www.atherosolve.com



PRESS RELEASE

AtheroSolve, Inc. gets exclusive license of CytoSolve's in silico models of atherosclerosis

Cambridge, April 12, 2017: In a milestone agreement, AtheroSolve, Inc. obtained exclusive licensing agreement for the in silico models from CytoSolve, Inc. These models will be used to accelerate the development of therapeutics for atherosclerosis.

"We are excited to have this agreement in place as it enables us to use CytoSolve's in silico models of atherosclerosis for discovering new combination drugs for atherosclerosis which then can be tested in the in vitro and in vivo settings," said Dr. Shiva Ayyadurai, Chief Executive Officer of AtheroSolve.

AtheroSolve is headquartered in Cambridge, MA. AtheroSolve uses CytoSolve's revolutionary technology for in silico mechanistic modeling is accelerating discovery and development of single and multi-combination therapeutics for atherosclerosis.

CytoSolve is headquartered in Cambridge, MA. CytoSolve's revolutionary technology for in silico mechanistic modeling is accelerating discovery and development of single and multi-combination therapeutics.